Literature DB >> 22451235

Hospital and medical care days in pancreatic cancer.

Casey A Boyd1, Daniel W Branch, Kristin M Sheffield, Yimei Han, Yong-Fang Kuo, James S Goodwin, Taylor S Riall.   

Abstract

BACKGROUND: Little is known about resource utilization (number of days in the hospital or medical care) between diagnosis and death in patients with pancreatic cancer.
METHODS: Using Surveillance, Epidemiology, and End Results (SEER)-Medicare linked data, we identified 25,476 patients with pancreatic cancer (1992-2005). Hospital and medical care days per person-month from the time of diagnosis were described, stratified by stage, treatment, and survival duration.
RESULTS: Hospital/medical care days vary by length of survival and treatment strategy in patients with pancreatic cancer. For all stages, patients were in the hospital a mean of 6.4 days and received medical care a total of 9.0 days in the first month after diagnosis, decreasing to 1.7 and 3.7 days per month, respectively, by the end of the first year. Hospital/medical care days per month of life were higher in patients with shorter survival but increased sharply at the end of life in all patients, regardless of duration of survival. In patients with locoregional disease, resection was associated with a higher number of hospital/medical care days during the first 4 months after diagnosis, but fewer at the end of the first year. For distant disease, hospital days were similar but days in medical care were higher for patients receiving chemotherapy, increasing especially at the end of life.
CONCLUSIONS: This study is the first to quantify hospital/medical care days in patients with pancreatic cancer by stage, treatment, and survival. This information will provide realistic expectations and allow for treatment decisions based on patient preferences.

Entities:  

Mesh:

Year:  2012        PMID: 22451235      PMCID: PMC3407309          DOI: 10.1245/s10434-012-2326-2

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  17 in total

1.  Quality of life after adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a prospective randomized controlled study.

Authors:  Marjolein J M Morak; Chulja J Pek; Erwin J O Kompanje; Wim C J Hop; Geert Kazemier; Casper H J van Eijck
Journal:  Cancer       Date:  2010-02-15       Impact factor: 6.860

2.  Quality of life and outcomes after pancreaticoduodenectomy.

Authors:  J J Huang; C J Yeo; T A Sohn; K D Lillemoe; P K Sauter; J Coleman; R H Hruban; J L Cameron
Journal:  Ann Surg       Date:  2000-06       Impact factor: 12.969

3.  Quality of life after curative or palliative surgical treatment of pancreatic and periampullary carcinoma.

Authors:  E J M Nieveen van Dijkum; K F D Kuhlmann; C B Terwee; H Obertop; J C J M de Haes; D J Gouma
Journal:  Br J Surg       Date:  2005-04       Impact factor: 6.939

4.  Preoperative factors predict perioperative morbidity and mortality after pancreaticoduodenectomy.

Authors:  David Yu Greenblatt; Kaitlyn J Kelly; Victoria Rajamanickam; Yin Wan; Todd Hanson; Robert Rettammel; Emily R Winslow; Clifford S Cho; Sharon M Weber
Journal:  Ann Surg Oncol       Date:  2011-02-20       Impact factor: 5.344

5.  Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up.

Authors:  Taylor S Riall; John L Cameron; Keith D Lillemoe; Jordan M Winter; Kurtis A Campbell; Ralph H Hruban; David Chang; Charles J Yeo
Journal:  Surgery       Date:  2006-08-28       Impact factor: 3.982

6.  A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine.

Authors:  Tudor E Ciuleanu; Alexander V Pavlovsky; Gyorgy Bodoky; Avgust M Garin; Virginia K Langmuir; Stewart Kroll; George T Tidmarsh
Journal:  Eur J Cancer       Date:  2009-01-31       Impact factor: 9.162

7.  Effect of combined treatment methods on quality of life in patients with pancreatic cancer.

Authors:  Panagiotis Heras; Konstantinos Kritikos; Antonios Hatzopoulos; Nikolaos Kritikos; Stefanos Karagiannis; Dimitrios Mitsibounas
Journal:  Am J Ther       Date:  2009 Jul-Aug       Impact factor: 2.688

8.  An alternative in terminal care: results of the National Hospice Study.

Authors:  D S Greer; V Mor; J N Morris; S Sherwood; D Kidder; H Birnbaum
Journal:  J Chronic Dis       Date:  1986

Review 9.  Surgical management of early-stage pancreatic cancer.

Authors:  Emmanuel E Zervos; Alexander S Rosemurgy; Osama Al-Saif; Alan J Durkin
Journal:  Cancer Control       Date:  2004 Jan-Feb       Impact factor: 3.302

10.  Comparing hospice and nonhospice patient survival among patients who die within a three-year window.

Authors:  Stephen R Connor; Bruce Pyenson; Kathryn Fitch; Carol Spence; Kosuke Iwasaki
Journal:  J Pain Symptom Manage       Date:  2007-03       Impact factor: 3.612

View more
  1 in total

1.  Clinical Data Prediction Model to Identify Patients With Early-Stage Pancreatic Cancer.

Authors:  Qinyu Chen; Daniel R Cherry; Vinit Nalawade; Edmund M Qiao; Abhishek Kumar; Andrew M Lowy; Daniel R Simpson; James D Murphy
Journal:  JCO Clin Cancer Inform       Date:  2021-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.